Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring

被引:17
作者
Chen, Lan [1 ]
Zhang, Yuan [1 ]
Zhang, Yi-Xin [1 ]
Wang, Wei-Lai [1 ]
Sun, De-Mei [1 ]
Li, Peng-Yun [2 ]
Feng, Xue-Song [1 ]
Tan, Yue [3 ]
机构
[1] China Med Univ, Sch Pharm, Shenyang 110122, Peoples R China
[2] Natl Engn Res Ctr Strateg Drugs, Inst Pharmacol & Toxicol Inst, Beijing 100850, Peoples R China
[3] China Med Univ, Dept Gastroenterol, Shengjing Hosp, Shenyang 110022, Peoples R China
关键词
TKIs; Microextraction technique; HRMS methods; Pharmacokinetic studies; Therapeutic drug monitoring; TYROSINE KINASE INHIBITORS; SOLID-PHASE EXTRACTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; RP-HPLC METHOD; TANDEM MASS-SPECTROMETRY; CHRONIC MYELOID-LEUKEMIA; WALLED CARBON NANOTUBE; UPLC-MS/MS METHOD; CLINICAL PHARMACOKINETICS; SIMULTANEOUS QUANTIFICATION;
D O I
10.1016/j.jpha.2023.11.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine kinase inhibitors (TKIs) have emerged as the first-line small molecule drugs in many cancer therapies, exerting their effects by impeding aberrant cell growth and proliferation through the modulation of tyrosine kinase-mediated signaling pathways. However, there exists a substantial interindividual variability in the concentrations of certain TKIs and their metabolites, which may render patients with compromised immune function susceptible to diverse infections despite receiving theoretically efficacious anticancer treatments, alongside other potential side effects or adverse reactions. Therefore, an urgent need exists for an up-to-date review concerning the biological matrices relevant to bioanalysis and the sampling methods, clinical pharmacokinetics, and therapeutic drug monitoring of different TKIs. This paper provides a comprehensive overview of the advancements in pretreatment methods, such as protein precipitation (PPT), liquid-liquid extraction (LLE), solid-phase extraction (SPE), micro-SPE (m-SPE), magnetic SPE (MSPE), and vortex-assisted dispersive SPE (VA-DSPE) achieved since 2017. It also highlights the latest analysis techniques such as newly developed high performance liquid chromatography (HPLC) and high-resolution mass spectrometry (HRMS) methods, capillary electrophoresis (CE), gas chromatography (GC), supercritical fluid chromatography (SFC) procedures, surface plasmon resonance (SPR) assays as well as novel nanoprobes-based biosensing techniques. In addition, a comparison is made between the advantages and disadvantages of different approaches while presenting critical challenges and prospects in pharmacokinetic studies and therapeutic drug monitoring. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of Xi'an Jiaotong University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:21
相关论文
共 192 条
  • [111] Effects of food on the pharmacokinetics of ponatinib in healthy subjects
    Narasimhan, N. I.
    Dorer, D. J.
    Niland, K.
    Haluska, F.
    Sonnichsen, Daryl
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (06) : 440 - 444
  • [112] Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry
    Ni, Mao-Wei
    Zhou, Jie
    Li, Hui
    Chen, Wei
    Mou, Han-Zhou
    Zheng, Zhi-Guo
    [J]. BIOANALYSIS, 2017, 9 (12) : 925 - 935
  • [113] A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers
    Ogama, Yoichiro
    Mineyama, Tomoko
    Yamamoto, Asuka
    Woo, Margaret
    Shimada, Naomi
    Amagasaki, Taro
    Natsume, Kazuto
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (03) : 351 - 359
  • [114] Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities
    Pasquini, Benedetta
    Orlandini, Serena
    Furlanetto, Sandra
    Gotti, Roberto
    Del Bubba, Massimo
    Boscaro, Francesca
    Bertaccini, Bruno
    Dousa, Michal
    Pieraccini, Giuseppe
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2020, 1611
  • [115] Patel D.M, 2019, J. Drug Deliv. Ther., V9, P28, DOI [10.22270/jddt.v9i6-s.3692, DOI 10.22270/JDDT.V9I6-S.3692]
  • [116] Clinical pharmacokinetics of imatinib
    Peng, B
    Lloyd, P
    Schran, H
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (09) : 879 - 894
  • [117] Ni0.5Zn0.5Fe2O4 nanoparticles-decorated poly (vinyl alcohol) nanofiber as resonance light scattering probe for determination of sunitinib in serum samples
    Pirdadeh-Beiranvand, Masoumeh
    Afkhami, Abbas
    Madrakian, Tayyebeh
    [J]. TALANTA, 2020, 218
  • [118] Magnetic molecularly imprinted electrospun nanofibers for selective extraction of nilotinib from human serum
    Pirdadeh-Beiranvand, Masoumeh
    Afkhami, Abbas
    Madrakian, Tayyebeh
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2020, 412 (07) : 1629 - 1637
  • [119] A New HPLC-UV Validated Method for Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Leukemic Patients
    Pirro, Elisa
    De Francia, Silvia
    De Martino, Francesca
    Fava, Carmen
    Ulisciani, Stefano
    Cambrin, Giovanna Rege
    Racca, Silvia
    Saglio, Giuseppe
    Di Carlo, Francesco
    [J]. JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2011, 49 (10) : 753 - 757
  • [120] A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas
    Portnow, Jana
    Badie, Behnam
    Markel, Susan
    Liu, An
    D'Apuzzo, Massimo
    Frankel, Paul
    Jandial, Rahul
    Synold, Timothy W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1634 - 1640